5 Reasons Genworth’s Would-Be Buyer Could Still Close the Deal
ACA Healthy Enrollee Bills Pound Aetna and Kaiser: Mark Farrah
Sicker people’s tendency to choose some health insurers’ individual plans over others is so strong, and so hard to predict, that some big health insurers are facing huge Affordable Care Act risk-adjustment....More>>>
As a wealth manager, I sometimes encounter clients who operate under the assumption that portfolio principal should never be touched for the purposes of supplementing their lifestyle. That is, they are hard-wired to believe that only portfolio income, such as dividends and interest—and never their principal — is available. I strongly disagree with this....More>>>
The whole point of all the gizmos, gadgets and freebies doled out by Amazon.com Inc. (NASDAQ: AMZN) is to make it so easy for consumers to buy from Amazon that shopping anywhere else becomes a big pain in the neck. The latest example is the company’s roll-out Tuesday of a new feature tied to its Alexa voice-command program: ordering an item from Prime Now, the company’s two-hour free....More>>>
Related CIG Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop Related PAM Mid-Morning Market Update: Markets Open Higher; Groupe Casino Offers To Buy Cnova ....More>>>
The venerable Merck (NYSE:MRK) has turned into a hot mega-cap stock again, at least hot for a non-Internet stock, on the back of its immuno-oncology drug Keytruda. Here’s a look at MRK’s movement – up almost 70%, plus dividends, in five years:
MRK data by YCharts
This article explains my indifference to going long MRK shares. Given that MRK....More>>>
In 1960, John B. Armstrong made a $5.4 trillion misjudgment. Armstrong was the father of the modern mutual fund. Today, most people know that mutual funds pool money to manage a portfolio. But at the time, few people had even heard of them. The entire industry only had about $2 billion in assets under management ("AUM") – roughly 1% of total American savings. Back....More>>>
NetApp seems almost ready to spread its wings – but many analysts think they have shot it down!
Is that hyperbole? It is important to carefully review what NetApp (NASDAQ:NTAP) has been able to accomplish since the new management team was appointed to clean up the wreckage wrought by the prior CEO and the team that had run the company almost to extinction.
Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.
The ability to increase the payloads of viral vectors....More>>>
April 11, 2017: Markets opened mixed Tuesday and investors’ efforts to cross into positive territory mostly fell short. Among the 11 S&P sectors, only real estate posted a decent gain, but that was more than offset by the sell-off in financial stocks. WTI crude oil for May delivery settled at $53.40 a barrel, up 0.6% on the day. June gold added 1.6% on the day to settle at $1,274.20, a....More>>>
Sales Trends A Bit Soft, But Nothing To Worry About
I have been a bit disappointed by Nordstroms (NYSE:JWN) recent results. Not because it was a bad quarter per se, but because it broke the sequence of constant overperformance compared to other peers in the
The last time we saw today's setup, one group of stocks more than doubled in four years and left U.S. stocks in the dust... It has nothing to do with China. And it might surprise you... European stocks are now dirt-cheap compared with their U.S. counterparts. Based on histo
US based but China focused small cap biopharmaceutical stockCASI Pharmaceuticals (NASDAQ: CASI) is up around 78% over the last three trading days on no apparent news on the newswires as the following chart illustrates:
CASI Pharmaceuticals is a U.S. based, late-stage small cap biop